Practice Essentials

Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
CME, CPE
Muhamed Baljevic, MD
Release Date: March 31, 2021
Expiration Date: March 31, 2022

In this activity, Dr. Baljevic discusses patients with newly diagnosed multiple myeloma who are eligible for transplant and reviews recent data from trials evaluating novel multi-drug combinations in the frontline setting. He also identifies the management of treatment-emergent adverse events that are associated with different treatment approaches.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
Overcoming Challenges in Smoldering Multiple Myeloma: Improving Diagnosis and Treatment Selection
Overcoming Challenges in Smoldering Multiple Myeloma: Improving Diagnosis and Treatment Selection
CME, CPE
Noopur Raje, MD
Release Date: January 18, 2021
Expiration Date: January 18, 2022

Smoldering multiple myeloma is an asymptomatic stage that occurs in between MGUS and active multiple myeloma. In this activity, Dr. Noopur Raje provides best practice regarding the diagnosis and management choice for patients with smoldering multiple myeloma. Furthermore, she describes the revised 20/2/20 risk stratification model and the implications on treatment decision making.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
Changing Standards in Transplant-Ineligible Patients Newly Diagnosed with Myeloma
Changing Standards in Transplant-Ineligible Patients Newly Diagnosed with Myeloma
CME, CPE
Saad Z. Usmani, MD, FACP
Release Date: November 30, 2020
Expiration Date: November 30, 2021

The treatment of transplant-ineligible patients with newly diagnosed myeloma remains a clinical challenge, but recent developments in novel therapeutic approaches have been shown to improve outcomes in these patients. In this activity, Dr. Usmani reviews the key clinical data in transplant-ineligible, newly diagnosed myeloma, and provides evidence-based recommendations for choosing individualized treatment regimens.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
View Only, CE ExpiredView Only, No Credit
 
Changing Treatment Paradigms in Heavily Pre-Treated RRMM Patients
Changing Treatment Paradigms in Heavily Pre-Treated RRMM Patients
CME, CPE
Sagar Lonial, MD, FACP
Release Date: May 20, 2020
Expiration Date: May 20, 2021

Treating patients with relapsed/refractory multiple myeloma (RRMM) has become more challenging with the introduction of new agents. In this activity, Dr. Lonial discusses the management of RRMM, given the new number of agents available, and which options are the best choice at the different stages of care. He will also review disease-related factors, treatment-related factors, and patient-related factors when considering treatment selection.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
Factors to Consider in the Treatment of Early Relapsed/Refractory Multiple Myeloma
Factors to Consider in the Treatment of Early Relapsed/Refractory Multiple Myeloma
CME, CPE
Sikander Ailawadhi, MD
Release Date: February 07, 2020
Expiration Date: February 07, 2021

Managing a newly diagnosed patient with multiple myeloma can present challenges. In this activity, Dr. Ailawadhi covers the key aspects of treatment for patients living with relapsed or refractory multiple myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
Optimizing Induction Therapy for Newly Diagnosed Multiple Myeloma: Navigating the Treatment Options
Optimizing Induction Therapy for Newly Diagnosed Multiple Myeloma: Navigating the Treatment Options
CME, CPE
Ajay K. Nooka, MD, MPH, FACP
Release Date: October 14, 2019
Expiration Date: October 14, 2020

Managing a newly diagnosed patient with multiple myeloma can present challenges. In this activity, Dr. Nooka covers the key aspects of management including the predictive measures currently available for risk stratification in newly diagnosed multiple myeloma (NDMM). He will also discuss the key clinical- and patient-related factors that could influence your choice of induction regimen, the safety and efficacy of the current modern day induction regimens in the frontline setting, as well as the role of monoclonal antibodies and the treatment of newly diagnosed myeloma patients in frontline setting.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
The Role of Maintenance Therapy for the Treatment of Multiple Myeloma
The Role of Maintenance Therapy for the Treatment of Multiple Myeloma
CME, CPE
Sarah A. Holstein, MD, PhD
Release Date: November 14, 2018
Expiration Date: November 14, 2019

Autologous stem cell transplant (SCT) continues to be the standard of care for eligible patients with multiple myeloma (MM) who can tolerate high-dose melphalan therapy. Although other treatment options are available to avoid relapse, the concept of continuous therapy after autologous SCT has been introduced and continues to be investigated in studies. In this activity, Dr. Sarah Holstein compares consolidation chemotherapy with maintenance treatment approaches from recent research on the efficacy and safety of new and emerging combinations. Dr. Holstein’s presentation focuses on maintenance therapy in the post-autologous SCT setting.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient
Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient
CME, CPE
Paul G. Richardson, MD
Release Date: October 29, 2018
Expiration Date: October 29, 2019

With many new and emerging drug classes for the treatment of relapsed/refractory multiple myeloma (RRMM), it can be challenging to determine the optimal approach to sequencing treatment for patients with the disease. This activity will compare efficacy and safety data on new and emerging therapies in RRMM and provide strategies for incorporating risk-adapted treatment decisions to optimize patient outcomes.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Novel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
CME, CPE
Shaji K. Kumar, MD
Release Date: June 27, 2018
Expiration Date: June 27, 2019

When managing newly diagnosed multiple myeloma (MM) patients, recommended diagnostic and treatment strategies are critical for optimizing outcomes. This activity will address how upfront testing strategies and current risk stratification processes support the identification of treatments that are tailored to each patient’s unique characteristics and needs.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
The Diagnostic Workup for Multiple Myeloma: Guidelines and Recommendations
The Diagnostic Workup for Multiple Myeloma: Guidelines and Recommendations
CME, CPE
Philip L. McCarthy, MD
Release Date: May 31, 2018
Expiration Date: May 31, 2019

Appropriate management of suspected and/or newly diagnosed multiple myeloma (MM) requires a full patient workup using guideline-based testing strategies and key laboratory tests. In this activity, Dr. Philip McCarthy outlines the important steps required for accurately diagnosing patients with suspected MM, and for using that information to develop effective, individualized treatment regimens.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
The Evolving Standard of Care in Relapsed/Refractory Multiple Myeloma
The Evolving Standard of Care in Relapsed/Refractory Multiple Myeloma
CME, CPE
Paul G. Richardson, MD
Release Date: December 14, 2017
Expiration Date: December 14, 2018

The advent of new therapeutic strategies in relapsed/refractory multiple myeloma (RRMM) has impacted the standard of care in clinical practice. With the potential for major changes to existing clinical recommendations, health care providers who treat patients with multiple myeloma must be prepared for implementation into practice. In this activity, participants will learn about the current treatment paradigms in RRMM and the new drug regimens that are being used as the standard of care in clinical practice. In addition, participants will gain an understanding of the potential impact of investigational therapies on the standard of care in relapsed/refractory disease.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
The Role of Maintenance/Consolidation Therapy in Multiple Myeloma: A Patient-Centered Approach
The Role of Maintenance/Consolidation Therapy in Multiple Myeloma: A Patient-Centered Approach
CME, CPE
Jacob Laubach, MD
Release Date: November 08, 2017
Expiration Date: November 08, 2018

Maintaining results of successful induction therapy is an important goal in the treatment of multiple myeloma. Recent advances in maintenance therapy indicate it is a viable approach, resulting in longer progression-free survival and, more importantly, overall survival. Ideally, maintenance therapy should sustain treatment responses, have good safety and tolerability profiles in long-term use, and be convenient for patients. Join Dr. Laubach as he navigates through a series of case presentations to provide you with the latest evidence and advances in clinical research to consider in this patient population.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Individualizing Patient Care: Navigating Drug Sequencing Strategies in Relapsed/Refractory Multiple Myeloma
Individualizing Patient Care: Navigating Drug Sequencing Strategies in Relapsed/Refractory Multiple Myeloma
CME, CPE
Saad Z. Usmani, MD, FACP
Release Date: October 25, 2017
Expiration Date: October 25, 2018

A major challenge in the treatment of patients with relapsed/refractory multiple myeloma (RRMM) is the selection of therapy among a multitude of treatment options. A number of factors must be considered when sequencing drugs, including but not limited to: efficacy and tolerability of prior therapies received; performance status and organ function; cytogenetic profile and other high-risk features; and characteristics of the relapse, such as timing and aggressiveness. In this activity, participants will learn about the recommended drug sequencing strategies that will help them in choosing therapy and individualizing treatment for their patients with RRMM.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Expanding Treatment Options for Newly Diagnosed Multiple Myeloma: Proteasome Inhibitors, Immunomodulatory Drugs, and Other Targeted Therapies
Expanding Treatment Options for Newly Diagnosed Multiple Myeloma: Proteasome Inhibitors, Immunomodulatory Drugs, and Other Targeted Therapies
CME, CPE
Sagar Lonial, MD, FACP
Release Date: September 27, 2017
Expiration Date: September 27, 2018

In recent years, advances in treatment have resulted in significantly improved outcomes and prognoses in patients with multiple myeloma; much of this research, however, was focused on the population of patients with relapsed or refractory disease. Today, a growing compendium of data and ongoing research is evaluating treatment options and management approaches specifically in patients with newly diagnosed multiple myeloma. Topics being evaluated include: when to treat smoldering versus symptomatic myeloma; factors to consider when selecting an induction regimen from among the current standard of care to new options investigated in the clinical trial setting; and the role of high-dose therapy consolidation and maintenance therapy. In this activity, Dr. Lonial summarizes the current state of research in each of these areas, and discusses the potential impact of the application of this information on improving outcomes and progression-free survival in patients with newly diagnosed multiple myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Developing Care Plans for Treatment-based Patient Monitoring in Relapsed/Refractory Multiple Myeloma
Developing Care Plans for Treatment-based Patient Monitoring in Relapsed/Refractory Multiple Myeloma
CNE
Beth Faiman, PhD, MSN, APRN-BC, AOCN®
Release Date: August 23, 2017
Expiration Date: August 23, 2018

Due to the increasing number of new treatment options for patients with relapsed/refractory multiple myeloma (RRMM), nurses must understand the key facets of patient monitoring required for development of care plans. In this activity, participants will learn about the major treatment-related adverse events and other critical aspects of patient monitoring, which must be incorporated into care plans for patients with RRMM being treated with the new drug regimens. In addition, there will be discussion of when and how to intervene for various events that may occur upon routine assessment and monitoring of patients receiving these agents.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma
Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma
CME, CPE
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Release Date: July 19, 2017
Expiration Date: July 19, 2018

The addition of new lenalidomide- and bortezomib-based drug regimens for patients with multiple myeloma increases the complexity of pharmacotherapeutic strategies, which must balance response benefit with tolerability. There are a number of comorbidities and treatment-related adverse events that must be appropriately assessed and monitored for, to ensure patient safety and prevent premature discontinuation of therapy. In this activity, Dr. Harvey will discuss hepatic and renal dysfunction, diabetes, and cardiovascular dysfunction, all of which can impact pharmacy-related decisions such as dose-modification, treatment interruption, or administration of concomitant medications.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Managing Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Managing Major Adverse Events in Relapsed/Refractory Multiple Myeloma
CME, CPE
Ajay K. Nooka, MD, MPH, FACP
Release Date: May 17, 2017
Expiration Date: May 17, 2018

Treatment-related adverse events (AEs) can have a significant impact on patients with multiple myeloma, including poorer outcomes, premature discontinuation of therapy, and reduced quality of life. There are a number of characteristic major AEs associated with treatment options for patients with relapsed/refractory disease, which must be monitored for and managed appropriately. In this activity, participants will learn about the major AEs associated with emerging and standard of care agents for relapsed/refractory multiple myeloma (RRMM), including clinical pearls for patient monitoring and toxicity mitigation strategies that can be implemented in clinical practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
View Only, CE ExpiredView Only, No Credit
 
Testing Strategies throughout the Myeloma Disease Lifecycle
Testing Strategies throughout the Myeloma Disease Lifecycle
CME, CPE
Philip L. McCarthy, MD
Release Date: April 26, 2017
Expiration Date: April 26, 2018

The diagnosis, prognostication, and assessment of patients with myeloma spans a gamut of testing strategies, including identification of key abnormal laboratory values, cytogenetic aberrations, and evidence of radiographic disease. In addition to new IMWG diagnosis criteria and the Revised ISS, various clinical strategies have been developed to identify high-risk patients and guide treatment decisions. In this activity, Dr. McCarthy will discuss presenting symptomatology and diagnostic recommendations for patients suspected of having multiple myeloma, including prognostic tests that should be considered as part of the initial workup. The activity will conclude with a discussion of patients who relapsed from complete remission, as well as those who developed frank disease progression.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
View Only, CE ExpiredView Only, No Credit
 
The Predictive Potential of Genomics in Multiple Myeloma
The Predictive Potential of Genomics in Multiple Myeloma
CME, CPE
Saad Z. Usmani, MD, FACP
Release Date: March 22, 2017
Expiration Date: March 22, 2018

Predictive markers have the potential to guide treatment selection and personalize therapeutic strategies for patients with multiple myeloma. Cytogenetic abnormalities, including del(17p), t(4;14) and t(14;16), are hallmarks of high-risk disease, but these genomic aberrations have also been implicated as potential predictive markers. Other genomic predictive markers are under investigation, such as t(14;20) and the SKY92 signature identified through gene expression profiling. In this activity, participants will learn about various genomic predictive markers under investigation and their potential to guide treatment decisions for patients with multiple myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
View Only, CE ExpiredView Only, No Credit